1994
DOI: 10.1002/ijc.2910560413
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The successful clinical experience with antibody LL2 (an IgG2a, anti-B-cell lymphoma antibody) in radioimmunodetection and radioimmunotherapy suggests that this antibody may have potential as a carrier of cytotoxic agents. The internalization, cellular trafficking, and catabolism of this antibody in target human Burkitt lymphoma cells (Raji) were investigated. Internalization of intact antibody as well as of the F(ab')2 and Fab' fragments was detected by an FITC-labeled anti-mouse second antibody probe, and ev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
30
0

Year Published

1996
1996
2014
2014

Publication Types

Select...
7
3

Relationship

3
7

Authors

Journals

citations
Cited by 68 publications
(30 citation statements)
references
References 16 publications
0
30
0
Order By: Relevance
“…The anti-CD22 mAbs were shown to internalize within minutes after cell-surface binding, 8,34 whereas anti-CD20 mAbs were generally slowly or not internalizing. 35 Internalization of the anti-CD20/22 bsAbs was investigated on Daudi cells by fluorescence microscopy.…”
Section: Characterization Of Recombinant Tetravalent Anti-cd20/22 Bsabsmentioning
confidence: 99%
“…The anti-CD22 mAbs were shown to internalize within minutes after cell-surface binding, 8,34 whereas anti-CD20 mAbs were generally slowly or not internalizing. 35 Internalization of the anti-CD20/22 bsAbs was investigated on Daudi cells by fluorescence microscopy.…”
Section: Characterization Of Recombinant Tetravalent Anti-cd20/22 Bsabsmentioning
confidence: 99%
“…Several investigators have proposed antibody internalization to be the cause of nonlinear clearance (5,12,15). Support for this idea comes from studies with labeled antibodies used for imaging or for targeting of cytotoxic agents (16)(17)(18). However, these latter studies were done at relatively low antibody dose.…”
Section: Introductionmentioning
confidence: 99%
“…98 Epratuzumab is a humanized anti-CD22 molecule that works by signal activation and induction of antibody-dependent cell cytotoxicity. 99 This drug, either alone or in combination with rituximab, has been studied in phase I and II trials of recurrent indolent and aggressive NHL.…”
Section: Other Targeted Therapiesmentioning
confidence: 99%